Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature.
暂无分享,去创建一个
Dyfrig Hughes | D. Hughes | M. Salas | Maribel Salas | Alvaro Zuluaga | Kawitha Vardeva | Maximilian Lebmeier | M. Lebmeier | A. Zuluaga | K. Vardeva
[1] K. Secnik,et al. Relationship of Glycemic Control to Total Diabetes-Related Costs for Managed Care Health Plan Members With Type 2 Diabetes , 2005, Journal of managed care pharmacy : JMCP.
[2] V. Basevi. Standards of medical care in diabetes--2007. , 2009, Diabetes care.
[3] A. Classification,et al. Standards of Medical Care in Diabetes—2009 , 2009, Diabetes Care.
[4] Yelena Rozenfeld,et al. Oral antidiabetic medication adherence and glycemic control in managed care. , 2008, The American journal of managed care.
[5] Taghreed Adam,et al. The burden and costs of chronic diseases in low-income and middle-income countries , 2007, The Lancet.
[6] S. Hahn,et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). , 2007, Investigative ophthalmology & visual science.
[7] J. Cramer,et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[8] C. Pashos,et al. Health Outcomes and Economic Impact of Therapy Conversion to a Biphasic Insulin Analog Pen Among Privately Insured Patients with Type 2 Diabetes Mellitus , 2007, Pharmacotherapy.
[9] S. Balu. Incremental treatment expenditure of diabetes in the United States. , 2007, Managed care interface.
[10] A. Palmer,et al. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of cost-effectiveness in the United States , 2007, Advances in therapy.
[11] T. Peters,et al. Cigarette smoking and adherence to antihypertensive medication in patients from primary care , 2007, The European journal of general practice.
[12] S. Majumdar,et al. Health Care Use and Costs in the Decade After Identification of Type 1 and Type 2 Diabetes , 2006, Diabetes Care.
[13] C. Pashos,et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. , 2006, Clinical therapeutics.
[14] J. Steiner,et al. A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.
[15] P. Phillips,et al. Gestational diabetes--worth finding and actively treating. , 2006, Australian family physician.
[16] F. Camacho,et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis. , 2006, Clinical therapeutics.
[17] C. Pashos,et al. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. , 2006, Managed care interface.
[18] Marsha A Raebel,et al. Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures , 2006, The Annals of pharmacotherapy.
[19] M. Cheang,et al. Validity of a Prescription Claims Database to Estimate Medication Adherence in Older Persons , 2006, Medical care.
[20] B. Bolinder,et al. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] S. Iyer,et al. Utilization and Costs for Compliant Patients Initiating Therapy With Pioglitazone or Rosiglitazone Versus Insulin in a Medicaid Fee-for-Service Population , 2006, Journal of managed care pharmacy : JMCP.
[22] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[23] P. Griner. Health care costs. , 2005, Annals of internal medicine.
[24] A. Lippman. Adherence to medication. , 2005, The New England journal of medicine.
[25] R. Verbrugge,et al. Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.
[26] H. Gerstein. Glycosylated Hemoglobin: Finally Ready for Prime Time as a Cardiovascular Risk Factor , 2004, Annals of Internal Medicine.
[27] Neil R. Powe,et al. Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.
[28] F. Camacho,et al. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis , 2004, Current medical research and opinion.
[29] J. Cramer. A systematic review of adherence with medications for diabetes. , 2004, Diabetes care.
[30] Carol M Mangione,et al. Diabetes Care Quality in the Veterans Affairs Health Care System and Commercial Managed Care: The TRIAD Study , 2004, Annals of Internal Medicine.
[31] J. Cramer. A Systematic Review of Adherence With Medications for Diabetes , 2004 .
[32] A. Vanderplas,et al. The Costs of Non-Adherence to Oral Antihyperglycemic Medication in Individuals with Diabetes Mellitus and Concomitant Diabetes Mellitus and Cardiovascular Disease in a Managed Care Environment , 2004 .
[33] N. Horton,et al. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. , 2004, Addiction.
[34] R. Tamblyn,et al. Validation of diagnostic codes within medical services claims. , 2004, Journal of clinical epidemiology.
[35] D. Share,et al. Costs and utilization associated with pharmaceutical adherence in a diabetic population. , 2004, The American journal of managed care.
[36] S. De Geest,et al. Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.
[37] F. Camacho,et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. , 2003, Clinical therapeutics.
[38] R Legood,et al. The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) , 2003, Diabetic medicine : a journal of the British Diabetic Association.
[39] C. Sherbourne,et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. , 2003, The American journal of medicine.
[40] J. Caro,et al. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. , 2002, Clinical therapeutics.
[41] M. Engelgau,et al. A Diabetes Report Card for the United States: Quality of Care in the 1990s , 2002, Annals of Internal Medicine.
[42] A Haycox,et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. , 2001, Health economics.
[43] S. Lewis,et al. Impact of rural hospital closures in Saskatchewan, Canada. , 2001, Social science & medicine.
[44] Joseph Conigliaro,et al. Problem drinking and medication adherence among persons with HIV infection , 2001, Journal of General Internal Medicine.
[45] E H Wagner,et al. Effect of improved glycemic control on health care costs and utilization. , 2001, JAMA.
[46] J. Apelqvist,et al. The inpatient care of patients with diabetes mellitus and foot ulcers. A validation study of the correspondence between medical records and the Swedish Inpatient Registry with the consequences for cost estimations , 2000, Journal of Internal Medicine.
[47] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[48] E. Wagner,et al. The use of automated data to identify complications and comorbidities of diabetes: a validation study. , 1999, Journal of clinical epidemiology.
[49] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[50] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[51] Anuja Roy,et al. Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[52] Femida Gwadry-Sridhar,et al. A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[53] F. Camacho,et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. , 2007, Clinical therapeutics.
[54] S. Majumdar,et al. Health care costs and mortality for Canadian urban and rural patients with diabetes: population-based trends from 1993-2001. , 2007, Clinical therapeutics.
[55] David B. Hogan,et al. Medication Nonadherence and Subsequent Risk of Hospitalisation and Mortality among Older Adults , 2006, Drugs & aging.
[56] Paula Williamson,et al. A comparison of multivariable regression models to analyse cost data. , 2006, Journal of evaluation in clinical practice.
[57] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .
[58] E. van Doorslaer,et al. Statistical analysis of cost outcomes in a randomized controlled clinical trial. , 1994, Health economics.
[59] M. de Luise,et al. Diabetes mellitus. , 1993, The Medical journal of Australia.
[60] S. Finkler. The distinction between cost and charges. , 1982, Annals of internal medicine.